{"id":943072,"date":"2026-03-10T06:43:58","date_gmt":"2026-03-10T10:43:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\/"},"modified":"2026-03-10T06:43:58","modified_gmt":"2026-03-10T10:43:58","slug":"biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\/","title":{"rendered":"BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">\n          <i>BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidates<\/i>\n        <\/li>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">\n          <i>BioNTech co-founders Ugur Sahin and \u00d6zlem T\u00fcreci will establish an independent\u00a0biotechnology company\u00a0to research and develop next-generation mRNA\u00a0innovations; management transition\u00a0by end of 2026<\/i>\n        <\/li>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">\n          <i>Both companies focus on distinct strategic priorities to maximize value for patients and shareholders, with BioNTech planning to contribute related rights and mRNA technologies to the new company in exchange for a minority stake<\/i>\n        <\/li>\n<li style=\"margin-top:0cm;margin-bottom:0cm;text-align:justify\">\n          <i>Signing of binding agreements expected by end of H1\/2026<\/i>\n        <\/li>\n<\/ul>\n<p align=\"justify\">\n        <b>Mainz, Germany, March 10, 2026 (GLOBE NEWSWIRE)<\/b> \u2013 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jANzsDfC9-Ih_S-8TXT-YJYNfltmdMlz2db0NOUBNHSa4DKtcx-lnNH-znQBTpWqNp9bdTJjq8bm9AnkdGGDGcERf0YU_3k_dRnfpnmNDBzmwRvyedc3y3w2C8GKFcE-\" rel=\"nofollow\" target=\"_blank\">BioNTech SE<\/a> (Nasdaq: BNTX, \u201cBioNTech\u201d or \u201cthe Company\u201d) today announced plans for an independent company to be established and led by BioNTech co-founders Prof. Ugur Sahin, M.D., and Prof. \u00d6zlem T\u00fcreci, M.D. The new company with distinct resources, operations and funding options, will advance next-generation mRNA innovations. BioNTech plans to contribute related rights and mRNA technologies to the new company to enable and support the prioritized development of next-generation mRNA innovations with disruptive potential. With both companies focusing on their respective strategic priorities, BioNTech expects to maximize value for patients and shareholders alike.<\/p>\n<p align=\"justify\">BioNTech is sharpening its strategic focus on the development and commercialization of its growing late-stage pipeline spanning innovative immunomodulator, antibody-drug conjugate (\u201cADC\u201d) and mRNA candidates. Its current clinical pipeline, including previously announced milestones and the COVID-19 vaccine franchise, remains unaffected by the plans for the new company: BioNTech expects to have 15 ongoing Phase 3 clinical trials in oncology by year end. 2026 will also be the first year in which the Company expects multiple late-stage data readouts across major cancer types. The clinical trials and resulting data will inform regulatory and launch plans.<\/p>\n<p align=\"justify\">Ugur Sahin and \u00d6zlem T\u00fcreci will transition into the management of their new company by the end of 2026 after their current service agreements end. BioNTech\u2019s Supervisory Board has initiated an executive search to identify successors for the positions to ensure a smooth transition and seamless execution of BioNTech\u2019s strategy.<\/p>\n<p align=\"justify\">\u201cOver the past 18 years, we have built BioNTech from a start-up into a global biopharmaceutical company with a strong and diversified pipeline. During the COVID-19 pandemic, we expanded beyond oncology to develop the first approved mRNA vaccine, helping to protect people worldwide. Today, the company is well positioned to advance its mission and evolve into a commercial multi-product company. None of this would have been possible without the extraordinary dedication of our teams, the trust of our shareholders and Supervisory Board, and the commitment of the partners who have supported us along the way. For us, this is the right time to prepare to hand over the baton,\u201d said<b> Prof. Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech. <\/b>\u201cAt the same time, \u00d6zlem and I are ready to become pioneers once again<b>.<\/b> Our vision has always been to translate our science into meaningful advances for patients, and we see extraordinary opportunities to unlock the next generation of transformative innovations.\u201d<\/p>\n<p align=\"justify\">\u201cOver the course of their careers, Ugur and \u00d6zlem have established an outstanding track record of innovation. As BioNTech advances multiple late-stage product candidates towards commercialization, we support them in taking the opportunity to apply their strengths and undivided attention to a new venture, dedicated to enabling mRNA-based technologies to reach their full potential,\u201d said <b>Helmut Jeggle, Chairman of the BioNTech Supervisory Board<\/b>. \u201cWe believe that this plan will be additive for both, BioNTech and the new company, as it aims to allow each organization to drive meaningful impact for patients. We look forward to working together with their new company on potential combination therapy approaches, setting the stage for continued success.\u201d<\/p>\n<p align=\"justify\">BioNTech co-founders and mRNA technology pioneers Prof. Ugur Sahin, M.D., and Prof. \u00d6zlem T\u00fcreci, M.D., will establish their third biotechnology company following the foundation of Ganymed Pharmaceuticals in 2001 and BioNTech in 2008. As a next-generation mRNA company, it is aimed at pioneering cutting-edge platform technologies and advancing the research and development of mRNA-based innovations with disruptive potential. To this end, BioNTech plans to contribute related rights and mRNA technologies to the new company on an arm\u2019s length basis in exchange for a minority stake and other forms of consideration such as milestones and royalties. It aims to benefit both companies by providing them with opportunities to collaborate on combination approaches involving their respective product candidates, with the potential to create new complementary or synergistic treatment strategies. A binding agreement is expected to be signed by the end of the first half of 2026 after which further details will be communicated by BioNTech.<\/p>\n<p align=\"justify\">\n        <b>About BioNTech<\/b><br \/>\n        <br \/>Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, Pfizer and Regeneron.<\/p>\n<p align=\"justify\">For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d8wqtJfzaSA59bkakqFXL39v1Ie9aPk9kWoPVh6JXSNkKBC8ljjBhuZekExNPJkfeLWK1CL89UNVSTM_tkLcklAHVpQIpY-iDB3GrkyKEyg=\" rel=\"nofollow\" target=\"_blank\">www.BioNTech.com<\/a>.<\/p>\n<p align=\"justify\">\n        <b>BioNTech Forward-Looking Statements<\/b><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: expected changes to BioNTech\u2019s leadership and the transition of responsibilities at the Management Board, including identification and recruitment of successors; the terms of the preliminary discussions between BioNTech and the co-founders, including the potential contribution of certain BioNTech assets to an independent company and the form of consideration payable to BioNTech; the timing for execution of definitive agreements between BioNTech and the co-founders; the companies\u2019 ability to collaborate on combination approaches for their product candidates; BioNTech\u2019s research and development programs, including its expectations regarding initiations of clinical trials; BioNTech\u2019s focus on building commercial capabilities for potential market launches; and BioNTech\u2019s expectations regarding the timing of, ability to obtain and maintain regulatory approval of, and planned readiness for, such launches. In some cases, forward-looking statements can be identified by terminology such as \u201cwill,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201caims,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond BioNTech\u2019s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: BioNTech\u2019s ability to reach definitive agreements with its co-founders; discussions with regulatory agencies regarding timing and requirements for additional clinical trials; the ability to produce comparable clinical results in future clinical trials; competition related to BioNTech\u2019s product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; the timing of and BioNTech\u2019s ability to obtain and maintain regulatory approval for BioNTech\u2019s product candidates; BioNTech\u2019s and its counterparties\u2019 ability to manage and source necessary resources; BioNTech\u2019s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech\u2019s third-party collaborators to continue research and development activities relating to BioNTech\u2019s development candidates and investigational medicines; BioNTech\u2019s and its collaborators\u2019 ability to commercialize and market its product candidates, if approved; BioNTech\u2019s ability to manage its development and expansion; regulatory developments in the United States and other countries and regions; BioNTech\u2019s ability to effectively scale its production capabilities and manufacture its product candidates; and other factors not known to BioNTech at this time.<\/p>\n<p align=\"justify\">You should review the risks and uncertainties described under the heading \u201cRisk Factors\u201d in BioNTech\u2019s Report on Form 6-K for the period ended December 31, 2025 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d8wqtJfzaSA59bkakqFXL2XNTEcbpVc0DWatXC_eNLQaPwQjCMOVQuKZWL-j2bZAM7RxG8-Jdb10grql_9ELoxIhN6F_HOPWhKjNtZFTsSq8bkt_QkwB6MW9-oLDfxyHje8a9j60ScX3sXFvbL9DfF_zXl_kmWWeLG0Vkiom90xS61n1HmrOKH8Od62ngTcO04fGuDq3lDdbX1bZ6o-WT8zIFPsiQOIHyomPhU43dd9FACP2TxgBfi0W7C_IBz6J5pgdkJvH_ZEEer3_rrj3MlvLdqDJFjinlq-oo_UrCjiB06G71nsIkxNZ4MkgPZeHLk4_RCPhJlYeZnfcvmf_Vmbenh-tzel7iYr1rJk_DxNceBjJfU38_LevviVDniv3N-cDX_6RoEXw2u9gUsuHeOX4jnEZuHVdFpUGUW_POX4=\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.<\/p>\n<p align=\"justify\">\n        <b>CONTACTS<\/b>\n      <\/p>\n<p>\n        <b>Media Relations<\/b><br \/>\n        <br \/>Jasmina Alatovic<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZcZvBUAs-KcehuUCe8VIO7u9Tn1srTFlqbtWbjXEqyDN58diEdW-YxVvM8qL-3WSkcozuCpMKIwKwj3xbseVr17wOyyxFNOa9y6171iFS4SCACsbLVCdfws0DR2-0AKMjL4K08PFU2kiZADNk_zbA-_IZRMTk5IoimfneU4ucAnpDVcFYLPcpQcXm7T7zikI_8XD6bOA4JiDDfjXc4zybmdZMf8frBrLbqeOlx2PM1aMVhfWWcGWQy3JyadIwmq3NNSrY7y9vtVrXMqpX2SlvA==\" rel=\"nofollow\" target=\"_blank\">Media@biontech.de<\/a><\/p>\n<p>\n        <b>Investor Relations<\/b><br \/>\n        <br \/>Douglas Maffei, PhD<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OknAMXbfSDBOsEAiLf2nSWzL3BImwlwBZ0kZJ8ahENCoEH3XPLTGmdUSSIdgdJToMwB1Yhczbvx_sca21eVm1QASV3DyZOX0PKzSoMZADsq4-RRe3bnIDU5_0dRWdFHH59wPAMTzN1z_y_HBFHA-OCdgQAtvilxNh3t00ug5juj7SfjD3XX3iyqb0EbISTwe1QopQYEDmIUnXD8xpZm96MJWzz13pXD5nH_GVG-9y0u6INQWSzoJdonIXrgKDUYgDokdb4GeiqfMlg5rHloLvA==\" rel=\"nofollow\" target=\"_blank\">Investors@biontech.de<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE2OTIzOCM0MDIzNTU4MjcjMjAwMDk4NQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/ZjYwMWM0ZmUtMzQ2OS00OWNjLWE3MTYtY2NiOTQ0MTRkYTAzLTEwMTI1NTgtMjAyNi0wMy0xMC1lbg==\/tiny\/BioNTech-SE.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidates BioNTech co-founders Ugur Sahin and \u00d6zlem T\u00fcreci will establish an independent\u00a0biotechnology company\u00a0to research and develop next-generation mRNA\u00a0innovations; management transition\u00a0by end of 2026 Both companies focus on distinct strategic priorities to maximize value for patients and shareholders, with BioNTech planning to contribute related rights and mRNA technologies to the new company in exchange for a minority stake Signing of binding agreements expected by end of H1\/2026 Mainz, Germany, March 10, 2026 (GLOBE NEWSWIRE) \u2013 BioNTech SE (Nasdaq: BNTX, \u201cBioNTech\u201d or \u201cthe Company\u201d) today announced plans for an independent company to be established and led by BioNTech co-founders Prof. Ugur Sahin, M.D., and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-943072","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidates BioNTech co-founders Ugur Sahin and \u00d6zlem T\u00fcreci will establish an independent\u00a0biotechnology company\u00a0to research and develop next-generation mRNA\u00a0innovations; management transition\u00a0by end of 2026 Both companies focus on distinct strategic priorities to maximize value for patients and shareholders, with BioNTech planning to contribute related rights and mRNA technologies to the new company in exchange for a minority stake Signing of binding agreements expected by end of H1\/2026 Mainz, Germany, March 10, 2026 (GLOBE NEWSWIRE) \u2013 BioNTech SE (Nasdaq: BNTX, \u201cBioNTech\u201d or \u201cthe Company\u201d) today announced plans for an independent company to be established and led by BioNTech co-founders Prof. Ugur Sahin, M.D., and &hellip; Continue reading &quot;BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-10T10:43:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE2OTIzOCM0MDIzNTU4MjcjMjAwMDk4NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030\",\"datePublished\":\"2026-03-10T10:43:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\\\/\"},\"wordCount\":1518,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE2OTIzOCM0MDIzNTU4MjcjMjAwMDk4NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\\\/\",\"name\":\"BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE2OTIzOCM0MDIzNTU4MjcjMjAwMDk4NQ==\",\"datePublished\":\"2026-03-10T10:43:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE2OTIzOCM0MDIzNTU4MjcjMjAwMDk4NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE2OTIzOCM0MDIzNTU4MjcjMjAwMDk4NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\/","og_locale":"en_US","og_type":"article","og_title":"BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030 - Market Newsdesk","og_description":"BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidates BioNTech co-founders Ugur Sahin and \u00d6zlem T\u00fcreci will establish an independent\u00a0biotechnology company\u00a0to research and develop next-generation mRNA\u00a0innovations; management transition\u00a0by end of 2026 Both companies focus on distinct strategic priorities to maximize value for patients and shareholders, with BioNTech planning to contribute related rights and mRNA technologies to the new company in exchange for a minority stake Signing of binding agreements expected by end of H1\/2026 Mainz, Germany, March 10, 2026 (GLOBE NEWSWIRE) \u2013 BioNTech SE (Nasdaq: BNTX, \u201cBioNTech\u201d or \u201cthe Company\u201d) today announced plans for an independent company to be established and led by BioNTech co-founders Prof. Ugur Sahin, M.D., and &hellip; Continue reading \"BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-10T10:43:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE2OTIzOCM0MDIzNTU4MjcjMjAwMDk4NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030","datePublished":"2026-03-10T10:43:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\/"},"wordCount":1518,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE2OTIzOCM0MDIzNTU4MjcjMjAwMDk4NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\/","name":"BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE2OTIzOCM0MDIzNTU4MjcjMjAwMDk4NQ==","datePublished":"2026-03-10T10:43:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE2OTIzOCM0MDIzNTU4MjcjMjAwMDk4NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE2OTIzOCM0MDIzNTU4MjcjMjAwMDk4NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-founders-led-new-company-as-biontech-advances-toward-becoming-a-multi-product-company-by-2030\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/943072","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=943072"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/943072\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=943072"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=943072"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=943072"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}